Leber's hereditary optic neuropathy: Difference between revisions

Content deleted Content added
Rescuing 2 sources and tagging 1 as dead. #IABot (v1.6.1)
Rescuing 1 sources and tagging 0 as dead. #IABot (v1.6.1) (Balon Greyjoy)
Line 47:
α-[[Tocotrienol]]-quinone, a [[vitamin E]] metabolite, has had some success in small open label trials in reversing early onset vision loss.<ref name="Shrader2011">{{Cite journal | last1 = Shrader | first1 = W. D. | last2 = Amagata | first2 = A. | last3 = Barnes | first3 = A. | last4 = Enns | first4 = G. M. | last5 = Hinman | first5 = A. | last6 = Jankowski | first6 = O. | last7 = Kheifets | first7 = V. | last8 = Komatsuzaki | first8 = R. | last9 = Lee | first9 = E. | doi = 10.1016/j.bmcl.2011.04.085 | last10 = Mollard | first10 = P. | last11 = Murase | first11 = K. | last12 = Sadun | first12 = A. A. | last13 = Thoolen | first13 = M. | last14 = Wesson | first14 = K. | last15 = Miller | first15 = G. | title = Α-Tocotrienol quinone modulates oxidative stress response and the biochemistry of aging | journal = Bioorganic & Medicinal Chemistry Letters | volume = 21 | issue = 12 | pages = 3693–3698 | year = 2011 | pmid = 21600768 | pmc = }}</ref><ref name="Sadun2011">[http://www.aosonline.org/annualmeeting/am_program.pdf Sadun, A et al. "EPI-743 alters the natural history of progression of Leber hereditary optic neuropathy". AOS meeting. May 2011] {{webarchive|url=https://web.archive.org/web/20110904044315/http://www.aosonline.org/annualmeeting/am_program.pdf |date=2011-09-04 }}</ref>
 
There are various treatment approaches which have had early trials or are proposed, none yet with convincing evidence of usefulness or safety for treatment or prevention including [[brimonidine]],<ref name="Newman2005">{{cite journal |vauthors=Newman NJ, Biousse V, David R, etal |title=Prophylaxis for second eye involvement in leber hereditary optic neuropathy: an open-labeled, nonrandomized multicenter trial of topical brimonidine purite |journal=Am. J. Ophthalmol. |volume=140 |issue=3 |pages=407–15 |date=September 2005 |pmid=16083844 |doi=10.1016/j.ajo.2005.03.058 |url=}}</ref> [[minocycline]],<ref name="pmid17822909">{{cite journal |vauthors=Haroon MF, Fatima A, Schöler S, etal |title=Minocycline, a possible neuroprotective agent in Leber's hereditary optic neuropathy (LHON): Studies of cybrid cells bearing 11778 mutation |journal=Neurobiol Dis |volume= 28|issue= 3|pages= 237–50|year=2007 |pmid=17822909 |doi=10.1016/j.nbd.2007.07.021}}</ref> [[curcumin]],<ref>Clinical Curcurmin trial recruiting at [http://clinicaltrials.nlm.nih.gov/ct2/show?cond=%22Optic+Nerve+Diseases%22&rank=10 ClinicalTrials.nlm.nih.gov] {{webarchive|url=https://web.archive.org/web/20090213192951/http://clinicaltrials.nlm.nih.gov/ct2/show?cond=%22Optic+Nerve+Diseases%22&rank=10 |date=2009-02-13 }}</ref>
[[glutathione]],<ref name="Ghelli2008" /> [[Infrared#Photobiomodulation|near infrared]] [[Light therapy|light treatment]],<ref name="WisconsinTrial">[http://www.mcw.edu/neurology/research/LHON.htm Wisconsin near infrared trial] {{webarchive|url=https://web.archive.org/web/20080515222915/http://www.mcw.edu/neurology/research/LHON.htm |date=2008-05-15 }}</ref> and [[viral vector]] techniques.<ref name="Qi"/>